Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merit Medical Systems, Inc. - Common Stock (NQ: MMSI )

100.45 +0.56 (+0.57%)
Streaming Delayed Price Updated: 11:36 AM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merit Medical Systems, Inc. - Common Stock

< Previous 1 2 3 Next >
Expert Ratings for Merit Medical Systems
Via Benzinga
Merit Medical Systems Q2 Beat Expectations: Analysts Say China/Russia Headwinds Hamper Guidance Raise
Tuesday, Merit Medical Systems Inc (NASDAQ: MMSI) announced Q2 FY23 revenue of $320.1 million, up 8.5% Y/Y, beating the  
Via Benzinga
Why Universal Health Services Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Silicon Motion Technology Corporation (NASDAQ: SIMO) shares climbed 78.9% to $93.40 following a report suggesting China approval of the company's Maxlinear merger. 
Via Benzinga
The Latest Analyst Ratings for Merit Medical Systems
Via Benzinga
Where Merit Medical Systems Stands With Analysts
Via Benzinga
Analyst Ratings for Merit Medical Systems
Via Benzinga
3 Top Healthcare Stocks to Buy for July
Three medical device stocks that make solid long-term investments. 
Via The Motley Fool
Merit Medical's Recent M&A Efforts Set To Show Early Impact In FY24: Analyst Insight
Barrington Research analyst Michael Petusky reiterated an Outperform rating on Merit Medical Systems, Inc. (NASDAQ: MMSI), with a  
Via Benzinga
Future Of Merit Medical Systems: Analyst Predictions On Revenue Growth And Operating Margin Improvement
Needham analyst Mike Matson reiterated a Buy rating on the shares of Merit Medical Systems, Inc. (NASDAQ: MMSI),  
Via Benzinga
AngioDynamics Divests Dialysis Portfolio And Biopsy Product Line To Merit Medical Systems For $100M
AngioDynamics, Inc. (NASDAQ: ANGO)  
Via Benzinga
Top 5 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Chart Of The Day: Merit Medical Systems - Strong Buy Sentiment
Revenue is predicted to grow 6.20% this year and another 5.30% next year. Earnings are estimated to increase by 7.40% this year, and an additional 10.00% next year. 
Via Talk Markets
Merit Medical To See Sustained Revenue Growth Despite Macro Headwinds, Bullish Analyst Says
Via Benzinga
Analyst Ratings for Merit Medical Systems
Via Benzinga
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
Via Benzinga
Lantheus Holdings Stock Showing Market Leadership; Earns 94 RS Rating
Lantheus Holdings stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 90 to 94. 
Via Investor's Business Daily
Merit Medical Systems: Q3 Earnings Insights
Merit Medical Systems (NASDAQ:MMSI) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
A Preview Of Merit Medical Systems's Earnings
Merit Medical Systems (NASDAQ:MMSI) is set to give its latest quarterly earnings report on Wednesday, 2022-10-26. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Recap: Merit Medical Systems Q2 Earnings
Merit Medical Systems (NASDAQ:MMSI) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Merit Medical Bullish On FY23 Operating Margin Of 18-21%, Needham Says Could Exceed
At the Annual Needham Healthcare Conference, Merit Medical Systems Inc's (NASDAQ: MMSI) management said that inflationary pressures and supply chain issues have been manageable and have not had a... 
Via Benzinga
Merger Arbitrage Mondays - Google (GOOG) Acquires Cybersecurity Firm Mandiant (MNDT)
Merger activity declined last week with three new deals announced and five deals completed. Two of the three new deals announced were potential deals in the works. I was surprised... 
Via Benzinga
Medical Device Maker Merit Medical Mulls Sale: Reuters
Merit Medical Systems Inc (NASDAQ: MMSI) is exploring options that include an outright sale to a private equity firm, Reuters reported citing people familiar with the... 
Via Benzinga
Recap: Merit Medical Systems Q4 Earnings
Merit Medical Systems (NASDAQ:MMSI) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
Merit Medical Systems Inc (MMSI) Q3 2021 Earnings Call Transcript
MMSI earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.